Trial Profile
Study H6Q-MC-JCCB A Phase 2, Open-Label, Multicenter Study of Single- Agent Enzastaurin in Patients with Relapsed Cutaneous T-Cell Lymphoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Oct 2020
Price :
$35
*
At a glance
- Drugs Enzastaurin (Primary)
- Indications Cutaneous T-cell lymphoma; Mycosis fungoides; Sezary syndrome
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 31 Mar 2010 Actual number of patients (25) added as reported by ClinicalTrials.gov record.
- 31 Mar 2010 Actual end date (1 Feb 2010) added as reported by ClinicalTrials.gov record.
- 31 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.